270 related articles for article (PubMed ID: 2441731)
1. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
Kuusela P; Haglund C; Roberts PJ; Jalanko H
Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
Jalanko H; Kuusela P; Roberts P; Sipponen P; Haglund CA; Mäkelä O
J Clin Pathol; 1984 Feb; 37(2):218-22. PubMed ID: 6198342
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of CA 125 in patients with gastrointestinal cancers.
Omar YT; al-Naqeeb N; el Nas SA; Awwad AH; Foudeh MO; Safadi NB; Nasralla MY; Ali MA; Szymendera JJ
Tumour Biol; 1989; 10(6):316-23. PubMed ID: 2480631
[TBL] [Abstract][Full Text] [Related]
4. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers.
Andriulli A; Gindro T; Piantino P; Farini R; Cavallini G; Piazzi L; Naccarato R; Dobrilla G; Verme G; Scuro LA
Digestion; 1986; 33(1):26-33. PubMed ID: 3940235
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Yoshikawa T; Nishida K; Tanigawa M; Fukumoto K; Kondo M
Digestion; 1985; 31(2-3):67-76. PubMed ID: 2581838
[TBL] [Abstract][Full Text] [Related]
8. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies.
Heptner G; Domschke S; Domschke W
Scand J Gastroenterol; 1989 Aug; 24(6):745-50. PubMed ID: 2814339
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
11. Tumour marker CA 125 in patients with digestive tract malignancies.
Haglund C; Kuusela P; Roberts P; Jalanko H
Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
[TBL] [Abstract][Full Text] [Related]
12. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
13. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
Tappero G; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1985 Apr; 76(16):765-70. PubMed ID: 2582313
[TBL] [Abstract][Full Text] [Related]
14. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
15. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
16. [An autopsy case of a gastric cancer associated with elevated AFP, CEA and CA19-9].
Nakamura Y; Hozumi T; Ohkita M; Masuda S; Maeda M; Okada K; Chinzei T; Yamashiro K; Harui M; Hosokawa I
Gan No Rinsho; 1988 Feb; 34(2):213-8. PubMed ID: 2450214
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of a new tumor serologic marker, CA 19-9: comparison with CEA.
Civardi G; Cerri L; Cavanna L; Fornari F; Di Stasi M; Binelli F
Tumori; 1986 Dec; 72(6):621-4. PubMed ID: 3468674
[TBL] [Abstract][Full Text] [Related]
18. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
19. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.
Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G
Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of carcinoembryonic antigen, gastrointestinal cancer-associated antigen and alphafetoprotein in staging and management of patients with advanced carcinoma of the stomach.
Szymendera JJ; Szawlowski AW; Nowacki MP; Kowalska M; Kaminska JA; Kozlowicz-Gudzinska I
Int J Biol Markers; 1987; 2(1):19-24. PubMed ID: 2448400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]